Evidence map›Paper›PMID 24376596›Full record

ArticlePloS one2013

The effect of acyclic retinoid on the metabolomic profiles of hepatocytes and hepatocellular carcinoma cells.

Xian-Yang Qin, Feifei Wei, Masaru Tanokura, Naoto Ishibashi, Masahito Shimizu, Hisataka Moriwaki, Soichi Kojima

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Metabolomic signatures of asthma-COPD overlap (ACO) are different from asthma and COPD.Metabolomics : Official journal of the Metabolomic Society · 2019
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Retinoid roles in blocking hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Xian-Yang QinMicro-signaling Regulation Technology Unit, RIKEN Center for Life Science Technologies, Wako, Saitama, Japan ; Japan Society for the Promotion of Science, Tokyo, Japan.
Feifei WeiDepartment of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo, Japan ; Japan Society for the Promotion of Science, Tokyo, Japan.
Masaru TanokuraDepartment of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo, Japan.
Naoto IshibashiTokyo New Drug Research Laboratories, Pharmaceutical Division, KOWA Company, Ltd., Tokyo, Japan.
Masahito ShimizuDepartment of Gastroenterology, Gifu University Graduate School of Medicine, Gifu, Japan.
Hisataka MoriwakiDepartment of Gastroenterology, Gifu University Graduate School of Medicine, Gifu, Japan.
Soichi KojimaMicro-signaling Regulation Technology Unit, RIKEN Center for Life Science Technologies, Wako, Saitama, Japan.
Gifu University · JPThe University of Tokyo · JPJapan Society for the Promotion of Science · JPKowa (Japan) · JPRIKEN · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background/purposeAcyclic retinoid (ACR) is a promising chemopreventive agent for hepatocellular carcinoma (HCC) that selectively inhibits the growth of HCC cells (JHH7) but not normal hepatic cells (Hc). To better understand the molecular basis of the selective anti-cancer effect of ACR, we performed nuclear magnetic resonance (NMR)-based and capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS)-based metabolome analyses in JHH7 and Hc cells after treatment with ACR. METHODOLOGY/PRINCIPAL

findingsNMR-based metabolomics revealed a distinct metabolomic profile of JHH7 cells at 18 h after ACR treatment but not at 4 h after ACR treatment. CE-TOFMS analysis identified 88 principal metabolites in JHH7 and Hc cells after 24 h of treatment with ethanol (EtOH) or ACR. The abundance of 71 of these metabolites was significantly different between EtOH-treated control JHH7 and Hc cells, and 49 of these metabolites were significantly down-regulated in the ACR-treated JHH7 cells compared to the EtOH-treated JHH7 cells. Of particular interest, the increase in adenosine-5'-triphosphate (ATP), the main cellular energy source, that was observed in the EtOH-treated control JHH7 cells was almost completely suppressed in the ACR-treated JHH7 cells; treatment with ACR restored ATP to the basal levels observed in both EtOH-control and ACR-treated Hc cells (0.72-fold compared to the EtOH control-treated JHH7 cells). Moreover, real-time PCR analyses revealed that ACR significantly increased the expression of pyruvate dehydrogenase kinases 4 (PDK4), a key regulator of ATP production, in JHH7 cells but not in Hc cells (3.06-fold and 1.20-fold compared to the EtOH control, respectively). CONCLUSIONS/SIGNIFICANCE: The results of the present study suggest that ACR may suppress the enhanced energy metabolism of JHH7 cells but not Hc cells; this occurs at least in part via the cancer-selective enhancement of PDK4 expression. The cancer-selective metabolic pathways identified in this study will be important targets of the anti-cancer activity of ACR.

Indexed as

Adenosine TriphosphateAnticarcinogenic AgentsCell Line, TumorElectrophoresis, CapillaryEnergy MetabolismGene ExpressionHepatocytesHumansMagnetic Resonance SpectroscopyMetabolomeOrgan SpecificityProtein Serine-Threonine KinasesPyruvate Dehydrogenase Acetyl-Transferring KinaseSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTretinoin3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acidAdenosine TriphosphateAnticarcinogenic AgentsPDK4 protein, humanProtein Serine-Threonine KinasesPyruvate Dehydrogenase Acetyl-Transferring KinaseTretinoin

Identifiers

PMID24376596
PMCPMC3871542
OpenAlexW2092082960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.